Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers

Germline mutations in BRCA1 or BRCA2 exist in ~2–7% of breast cancer patients, which has led to the approval of PARP inhibitors in the advanced setting. We have previously reported a phase II neoadjuvant trial of single agent talazoparib for patients with germline BRCA pathogenic variants with a pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xuan, Ge, Zhongqi, Yang, Fei, Contreras, Alejandro, Lee, Sanghoon, White, Jason B., Lu, Yiling, Labrie, Marilyne, Arun, Banu K., Moulder, Stacy L., Mills, Gordon B., Piwnica-Worms, Helen, Litton, Jennifer K., Chang, Jeffrey T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090765/
https://www.ncbi.nlm.nih.gov/pubmed/35538088
http://dx.doi.org/10.1038/s41523-022-00427-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090765/
https://www.ncbi.nlm.nih.gov/pubmed/35538088
http://dx.doi.org/10.1038/s41523-022-00427-9

Ejemplares similares